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Susceptibility of Plasmodium falciparum to the drugs used to
treat severe malaria (quinine) and to prevent malaria
(mefloquine, cycloguanil) in Comoros Union and Madagascar
Milijaona Randrianarivelojosia, Laurence Randrianasolo, Rindra V Randremanana, Arthur Randriamanantena, Arsène
Ratsimbasoa, Jean-Désiré Rakotoson
Objectives. To monitor the sensitivity of Plasmodium falciparum
to the drugs used to treat severe malaria and to prevent
malaria in Comoros and Madagascar.
Design. We used the in vitro isotopic method to test the
sensitivity of P. falciparum to quinine, mefloquine and
cycloguanil. 
Results. We tested fresh isolates of P. falciparum, collected from
patients living in urban, suburban and rural areas and
suffering from uncomplicated malaria in 2001, against at least
one of the antimalarials cited above. In both countries all of
the successfully tested isolates were sensitive to quinine 
(N = 243) and to cycloguanil (N = 67). The mean IC50 ranged
from 85.7 to 133.7 nM for quinine. For cycloguanil, the mean
IC50 ranged from 1.4 to 20.2 nM and the highest IC50 value
(102.5 nM) was recorded in Comoros. Only 0.9% (1/110) of
the informative isolates from Madagascar were mefloquine-
resistant (0/18 in Comoros). The mefloquine mean IC50s were
8.2 nM, 14.1 nM and 11.6 nM respectively in the rural,
suburban and urban areas of Madagascar, and 5.9 nM in
Comoros. A positive correlation was found between quinine
and mefloquine IC50s (N = 127, r = 0.48, p < 10- 6), but in vitro
mefloquine was 6 - 16 times more potent than quinine. No
correlation was noticed between the activities of quinine and
cycloguanil or between the activities of mefloquine and
cycloguanil. 
Conclusion. We therefore advocate the use of a full-course
regimen of quinine, as recommended by the World Health
Organisation (WHO), to treat above all severe malaria in
Madagascar and Comoros. Our results also demonstrate that
the use of mefloquine- and cycloguanil-based antimalarials is
still justified to prevent malaria in both countries, mainly in
the case of travellers.
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Knowledge of the efficacy of antimalarial drugs in malarial
countries is vital in adapting malaria chemotherapy and
chemoprophylaxis strategies. Chloroquine resistance now
occurs almost in every area where Plasmodium falciparum
circulates. Resistance to most of the commonly used
antimalarials including mefloquine has been documented.1
Over the past five decades, chloroquine has been used to cure
and/or to prevent malaria in Comoros Union and in
Madagascar. Chloroquine resistance is not currently a real
concern in Madagascar, even though cases of chloroquine
treatment failure and chloroquine chemoprophylaxis failure led
to the over-hasty description of resistance.2-4 In contrast, in the
Comoros Union the prevalence of chloroquine resistance is
high.5 Chloroquine treatment fails in 60% of children under 5
years of age in the three islands of the archipelago (Silai et al.
— unpublished data).
Quinine is the main treatment for severe malaria in Comoros
and Madagascar. Mefloquine and cycloguanil-based
antimalarial drugs are recommended for the prevention of
malaria, particularly for travellers.6,7 Very few in vivo or in vitro
tests have been done to assess the chemosusceptibility of 
P. falciparum in this part of the Indian Ocean subregion. In 2000,
the Madagascan Ministry of Health renewed the challenge to
get updated data on the effectiveness of antimalarial drugs, in
collaboration with the Malaria Research Group of the Institut
Pasteur de Madagascar (IPM). As part of this project, in vitro
tests were carried out on fresh P. falciparum isolates to monitor
their susceptibility to the drugs recommended and used for
severe malaria therapy and for malaria prevention in
Madagascar. In early 2001, the Comorian health policy makers
asked the IPM for expert help in assessing malaria resistance.
We report here on the sensitivity of P. falciparum in both
countries to quinine, mefloquine and cycloguanil.
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Materials and methods
Study sites and collection of P. falciparum isolates 
Madagascar is a large island measuring 587 000 km2. 
P. falciparum isolates were collected from a number of sites in
the rural, suburban and urban areas within the three regions of
different Plasmodium transmission patterns.8 The collection sites
were, from north to south, Antsiranana, Mahajanga, Ranohira,
Morondava and Toliara in the west region (malaria
transmission period < 6 months per year); Antananarivo and
Saharevo in the central region (malaria transmission period < 4
months per year and unstable); and Sambava, Sainte Marie,
Toamasina, Mananjary and Esana in the east region (malaria
transmission period > 6 months per year). The town of Moroni
was the collection site in the Comoros Union. Thick blood
smears were prepared for each outpatient attending the health
centres at study sites with suspected malaria. These smears
were Giemsa-stained and examined with a light microscope to
determine whether malaria parasites were present. Patients
presenting with signs and symptoms of severe and
complicated malaria, as defined by the World Health
Organisation (WHO),9 were excluded. Blood samples 
(2 - 5 ml) were collected from consenting patients (or patients
whose guardians or parents gave consent) by venepuncture.
The samples were collected in citric acid dextrose. They were
transported at +4°C to the malaria research group at the IPM in
Antananarivo within 48 hours of the blood collection. Patients
were treated for malaria by the local physician according to the
recommendation of the national policy, without immediate or
delayed follow-up. The Madagascan and the Comorian
Ministries of Health approved the study protocol.
Antimalarial drugs tested
Cycloguanil was obtained from Zeneca, quinine base from
Sigma Chemicals and mefloquine from Roche Products. Sterile
stock solutions were prepared in methanol/water and serial
dilutions were made in distilled water. Test concentrations
ranged from 0.3 to 32 000 nM for cycloguanil, from 2.5 to 400
nM for mefloquine and from 25 to 3 200 nM for quinine. In
vitro chemosensitivity tests were performed according to the
isotopic microtest method10 as described elsewhere.11 Rosewell
Park Memorial Institute (RPMI) 1640 medium (Gibco, BRL,
France) was used to test the quinoline-containing antimalarials
(mefloquine and quinine). RPMI medium without p-
aminobenzoic and without folic acid (Biowhittaker Europe, A
Cambrex Company, Belgium) was used to test cycloguanil.
Both media were supplemented with 10% (volume/volume)
non-immune human-type AB-positive serum. [3H]-
hypoxanthine was added to a concentration of 1 µCi per well
on the culture plate. Characterised P. falciparum clones 3D7 and
FCM29, maintained in continuous culture in our laboratory,
were used as references to test the quality of each batch of
dosed plates.
Data analysis
The concentration of the test antimalarials required to inhibit
the growth of 50% of the parasites (IC50) was calculated using
regression analysis of log concentration/response probit
curves. An isolate was considered to be resistant when the IC50
was > 800 nM for quinine, > 50 nM for mefloquine, and 500 nM
for cycloguanil.11-13 Results are expressed as the mean IC50 and
95% confidence intervals (95% CI). Epi-Info 6 software was
used to compare mean IC50s. The correlation between the in
vitro sensitivity of P. falciparum to two different drugs, based on
IC50 values, was analysed using Pearson’s correlation. 
Results
Between January and December 2001, 613 blood samples
containing P. falciparum were sent to the Malaria Research
Group of the IPM. Only monospecific P. falciparum isolates
were tested when at least 2 000 ring stage parasites were
detected per microlitre of blood, and if patients had not
recently (< 7 days) taken antimalarial drugs. Thus, 350 isolates
(57.1%) were tested against at least one of the antimalarials
cited above. The results from areas of the same category (rural,
suburban and urban) were considered together (Tables I 
and II).
Quinine
In Madagascar, successfully tested P. falciparum isolates were
sensitive to quinine (N = 215). However, the differences
between the mean IC50s were statistically significant (p < 10-6)
in the rural, suburban and urban areas of Madagascar. The
mean IC50 was 133.7 nM (95% CI: 107.5 - 160 nM) in the urban
area of Madagascar, which is 1.56 times higher than the mean
IC50s observed in the rural area. The highest IC50 (548.2 nM)
was detected in Madagascar. In Comoros, the 28 successfully
tested isolates were sensitive to quinine (mean IC50 = 96.2 nM,
95% CI: 68.7 - 123.7 nM).
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Table I. Plasmodium falciparum isolates collected and tested
against at least one antimalarial drug (N = 248)
Collection Collected In vitro Assessable 
areas isolates tests done tests
Madagascar
Rural 313 139 109
Suburban 78 57 53
Urban 160 106 57
Subtotal 551 302 219
Comoros Union
Urban 62 48 29
Total 613 350 248
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Mefloquine 
Successfully tested P. falciparum isolates were mefloquine-
sensitive, except 1 of the 110 (0.9%) from Madagascar. This
parasite of mefloquine-resistant phenotype was collected from
the suburban area of Mananjary, in the south-eastern part of
the island. The mean IC50s were 8.2 nM (95% CI: 6.8 - 9.6 nM),
14.1 nM (95% CI: 8.7 - 19.5 nM) and 11.6 nM (95% CI: 9.3 - 13.9
nM) respectively in the rural, suburban and urban areas. The
differences between the mean IC50s were statistically
significant between the three areas categories in Madagascar 
(p = 0.007). Nevertheless, virtually all P. falciparum isolates from
this part of the Indian Ocean region were sensitive to
mefloquine. For all regions combined, 82.8% (106/128) of the
IC50 values were below 15 nM (94.4% in Comoros and 80.9%
in Madagascar). The only IC50 value over 15 nM (1/18)
recorded in Comoros was 26.3 nM.
Cycloguanil
Of the 139 tests carried out with cycloguanil, 67 (48.2%) were
assessable. The 56 successfully tested Madagascan isolates
were highly sensitive to cycloguanil. The IC50s were always
below 50 nM. However, 1 of the 11 Comorian isolates showed
decreased sensitivity to cycloguanil, with an IC50 value 
> 100 nM. The differences between the mean IC50s in
Madagascar and in Comoros were not significant. 
Correlation between drug activities
Table III shows the correlations between drug activities based
on the IC50 values. Data from Madagascar and Comoros were
considered together. Significant positive correlation was found
between the susceptibility of P. falciparum to mefloquine and to
quinine in this part of the Indian Ocean subregion (N = 127,
Pearson’s r = 0.48, p < 10-6). The mean quinine IC50/mean
Table II. Mean IC50s with 95% confidence intervals (95% CI) for quinine, mefloquine and cycloguanil
Study areas
Madagascar Comores
Antimalarial drugs tested Rural Suburban Urban (urban)
Quinine
Assessable tests 107 53 55 28
Mean IC50s (nM) 85.7 90.2 133.77 96.2
IC50s 95% CI 75.6 - 95.9 76.3 - 104 107.5 - 160 68.7 - 123.7
Highest IC50 (nM) 280.4 214.3 584.2 313.2
Resistant isolates (N) 0 0 0 0
Mefloquine
Assessable tests 56 22 32 18
Mean IC50s (nM) 8.2 14.1 11.6 5.9
IC50s 95% CI 6.8 - 9.6 8.7 - 19.5 9.3 - 13.9 3.4 - 8.4
Highest IC50 (nM) 27.8 53.2 29.8 26.3
Resistant isolates (N) 0 1 0 0
Cycloguanil
Assessable tests 23 14 19 11
Mean IC50s (nM) 6.1 1.4 7.2 20.2
IC50s 95% CI 1.7 - 10.6 0.9 - 1.9 3.1 - 11.3 1.6 - 38.8
Highest IC50 (nM) 48.2 3.2 35.1 102.5
Resistant isolates (N) 0 0 0 0
Table III. Correlations between Plasmodium falciparum isolate sensitivities to quinine, mefloquine and cycloguanil in vitro in Comoros Union
and Madagascar
Drug pair Isolate number r r2 p-level*
Quinine-mefloquine 127 0.48 0.234 < 10-6
Quinine-cycloguanil 63 - 0.09 0.009 0.47
Mefloquine-cycloguanil 62 - 0.16 0.026 0.21
* Correlation is significant for p < 0.05.
mefloquine IC50 ratio ranged from 6.4 to16.3. No sign of
correlation was observed between the activities of quinine and
cycloguanil or between the activities of mefloquine and
cycloguanil.
Discussion
We used the in vitro sensitivity test to assess the intrinsic
activity of antimalarial drugs. In vitro and in vivo investigations
recently confirmed that chloroquine resistance of P. falciparum
is a concern in Comoros,5 whereas P. falciparum chloroquine
susceptibility and chloroquine therapeutic efficacy are still
satisfactory in Madagascar.4,14,15 Interestingly, Jambou et al.16
reported the therapeutic effectiveness of a 3-day regimen of
oral quinine to treat uncomplicated malaria in Madagascar. The
efficacy of quinine in areas of drug resistance in Africa17-20
supports the use of quinine for the management of
recrudescent P. falciparum following the use of chloroquine or
other antimalarial drugs.
Our results show that Comorian and Madagascan 
P. falciparum strains are sensitive to quinine. These results
suggest that quinine can be used to treat either severe or
recrudescent P. falciparum malaria in these countries — using
the full-course quinine regimen as recommended by the
WHO.21
However, the unsupervised use of quinine has been
observed in urban areas of Madagascar. It is common for
suspected and confirmed cases of malaria to be treated with
quinine (three daily intramuscular injections) in main towns.
Most of the time the dose administered is insufficient. We
found that the quinine IC50s were almost 1.6 times higher in
urban areas than rural areas. This raises the question as to
whether drug pressure related to quinine use in urban areas
may select parasites with decreased sensitivity to quinine. It is
therefore essential that the therapeutic efficacy of quinine also
be monitored. The annual publication of national standard
practice guidelines for the use of antimalarials may help to
control the misuse of quinine and keep health carers,
physicians and practitioners informed. 
Our results also show that mefloquine was 6.4 - 16.3 times
more potent than quinine and that there is a correlation
between the sensitivity of P. falciparum to the two drugs. The
structural similarities between quinine and mefloquine might
explain this correlation. All successfully tested Comorian 
P. falciparum isolates were sensitive to mefloquine and only 1
(0.9%) mefloquine-resistant P. falciparum isolate was detected in
Madagascar. Even if the IC50 threshold for mefloquine
resistance is still unclear, our previous studies15,22 also detected
a low rate (3.9% in 1997 and 2% in 1999) of mefloquine-
resistant P. falciparum in Madagascar. Mefloquine is mainly
advocated for the prevention of malaria in travellers in the
malaria areas of the Indian Ocean region. The occurrence of
potentially mefloquine-resistant parasites will hamper the
prevention strategy. The need for relevant and up-to-date data
on the effectiveness of mefloquine means that we need to
monitor its efficacy for prophylaxis in pilot studies. In vitro
sensitivity testing should be continued until the mechanism
underlying mefloquine resistance is understood. 
Regarding the readout of the in vitro sensitivity/resistance of
isolates to cycloguanil, low tritium-labelled hypoxanthine
incorporation was noted in non-assessable tests (less than 
1 000 counts/min in the controls). This might be due to the lack
of folic and p-aminobenzoic acid in culture medium used to
test antifolates.12 Even though the number of assessable tests
was limited, our results showed that P. falciparum is highly
sensitive to this drug in Madagascar. Few isolates with
decreased sensitivity to cycloguanil seem to occur in Comoros.
Basically, the combination of chloroquine plus cycloguanil for
prevention of malaria is still recommended in Madagascar. In
Comoros, we presume that the same combination can currently
be used and that mefloquine is still recommended to prevent
malaria. The increasing prevalence of chloroquine-resistant 
P. falciparum in the Comoros commonly leads to increased use
of the combination sulfadoxine-pyrimethamine for malaria
treatment. As cycloguanil is also a dihydrofolate reductase
(DHFR) inhibitor, like pyrimethamine, particular attention
should be paid to the use of cycloguanil-based antimalarials in
the Comoros over the next decade. Molecular approaches14,23
should be used for surveillance of P. falciparum cycloguanil
resistance/susceptibility. 
Conclusion
Drug resistance in malaria is a vital public health concern. The
resistance pattern in each country provides useful guidance
concerning treatment and prevention, because no bedside
methods are available to assess antimalarial drug susceptibility.
Our in vitro study demonstrated that P. falciparum parasites are
generally sensitive to quinine, mefloquine and cycloguanil in
Comoros Union and in Madagascar. These results justify the
use of quinine for the treatment of severe malaria, and the
prescription of mefloquine- and cycloguanil-based
antimalarials for malaria prophylaxis in this part of the Indian
Ocean.
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Toxoplasmosis is the most frequent cause of focal cerebral
lesions in patients with AIDS.1 Current therapy for acute
cerebral toxoplasmosis is a combination of pyrimethamine plus
sulfadiazine.2 Alternative agents include clindamycin,
clarithromycin and azithromycin.3,4 In addition to the
significant adverse effect profile of the pryimethamine
combination, necessitating folinic acid replacement, none of
these agents is available in intravenous form in most public
service hospitals within the province of KwaZulu-Natal. The
combination of trimethoprim-sulfamethoxazole (co-
trimoxazole) has been shown to possess antitoxoplasmic
activity in vitro3 and in vivo.5,6 The latter study,6 a retrospective
appraisal of intravenous therapy, showed a favourable
outcome in 87% of treated patients. The aim of the present
study was to prospectively evaluate the efficacy of oral co-
trimoxazole in acute cerebral toxoplasmosis.
Oral trimethoprim-sulfamethoxazole in the treatment of
cerebral toxoplasmosis in AIDS patients — a prospective
study
P Francis, V B Patel, P L A Bill, A I Bhigjee
Toxoplasma encephalitis is the commonest cause of
intracranial mass lesions in AIDS patients. Effective therapy
includes  pyrimethamine plus sulfadiazine, clindamycin
with pyrimethamine, and co-trimoxazole. This study
examines the efficacy of oral co-trimoxazole in 20 AIDS
patients with toxoplasmosis and seeks to confirm the
experience of Torre et al.
S Afr Med J 2004; 94: 51-53.
